Read More

CytoMed Therapeutics Announces China Research Collaboration To Enhance Its Allogeneic CAR γδ T In Vivo Persistency; The MOU Signed By Cytomed And Hangzhou CNK Therapeutics Co., Ltd Is The First Of Several Collaborative Efforts In North Asia

The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first of several collaborative efforts in North Asia.   SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- CytoMed Therapeutics

GDTC